PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.
The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.
Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.
Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
Bladder cancer is one of the most commonly diagnosed cancer in the United States- yet it remains one of the least talked about. As Bladder Cancer Awareness Month begins, the Bladder Cancer Advocacy Network (BCAN) is urging the country to pay attention to a disease that affects more than 725,000 people nationwide, with over 84,000 new cases expected this year.
Trulieve Cannabis Corp. (TCNNF) has officially filed applications with the Drug Enforcement Administration to register certain state-sanctioned medical marijuana operations using a new faster track for approval.
An artificial intelligence or AI tool developed by Mayo Clinic can help doctors find pancreatic cancer much earlier than usual, even up to three years before it is normally diagnosed. "The greatest barrier to saving lives from pancreatic cancer has been our inability to see the disease when it is...
Incyte (INCY) announced that the U.S. Food and Drug Administration has approved Jakafi XR (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF), adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant...